Trial data show daraxonrasib extended survival in previously treated metastatic pancreatic cancer
The facts
- A clinical trial found that daraxonrasib improved survival compared with chemotherapy in patients with previously treated metastatic pancreatic cancer.
- Multiple reports said the trial included 500 patients.
- Reported average survival was 13.2 months for patients receiving daraxonrasib versus 6.6 months for patients receiving chemotherapy.
- Daraxonrasib was reported as a once-daily oral pill in the trial.
- Several reports said daraxonrasib caused fewer severe side effects than chemotherapy.
- The trial results were presented at the American Society of Clinical Oncology meeting in Chicago and were published in The New England Journal of Medicine.
- Reports said daraxonrasib targets KRAS-related tumor growth, and KRAS mutations are found in more than 90% of pancreatic cancers.
- The drug is still experimental, and at least one report said it has been fast-tracked by the U.S. Food and Drug Administration for approval.
Context
Who were the patients in this trial?
The study involved patients with metastatic pancreatic cancer whose disease had already been treated and was no longer responding to prior chemotherapy; reports also describe the trial as enrolling 500 patients across North America, Europe and Asia BBC,India Today,Yahoo! Finance.
How does daraxonrasib work?
Reports say daraxonrasib blocks KRAS-driven tumor growth. That matters because KRAS mutations are found in more than 90% of pancreatic tumors, making it a widely relevant target in this cancer Yahoo! Finance,Independent,CBS News.
Common ground, and where they split
- Common ground
- An experimental once-daily pill beat chemotherapy in previously treated metastatic pancreatic cancer on both survival and severe side effects, a result serious enough to suggest KRAS-targeted treatment may offer a more effective, more tolerable path than standard care.
- Where Left and Right split
- Less a disagreement than a question of emphasis: a more tolerable, more precisely targeted direction for care versus the strength and credibility of a 500-patient result presented at ASCO and published in The New England Journal of Medicine.
How left and right read it
This result stands out because an experimental treatment not only improved survival over chemotherapy in previously treated metastatic pancreatic cancer, but did so with reported average survival of 13.2 months versus 6.6 months and fewer severe side effects. A once-daily oral pill that targets KRAS-related tumor growth in a disease where KRAS mutations are found in more than 90% of cases points to a more tolerable, more precisely targeted direction for care.
This result stands out because an experimental once-daily oral pill in a 500-patient trial reportedly doubled average survival over chemotherapy, from 6.6 months to 13.2 months, while also causing fewer severe side effects. With findings presented at ASCO and published in The New England Journal of Medicine, it’s a serious signal that targeted treatment of KRAS-related tumor growth may be delivering real gains.
The receipts — 95 sources
Wire services (4)
Other coverage (91)
A news briefing built to show both sides.
The day’s biggest stories in one short brief, built to show both sides and the competing values behind the headlines. Free in your inbox.